Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NSCLC, metastatic

1911 - Ceritinib in ROS1-rearranged non-small-cell lung cancer: a Korean nationwide phase II study


09 Oct 2016


NSCLC, metastatic


Sun Min Lim


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


S.M. Lim1, B.C. Cho2, H.R. Kim3, J. Lee4, K.H. Lee5, Y. Lee6, Y.J. Min7, E.K. Cho8, S. Lee9, B. Kim10, M.Y. Choi11, H.S. Shim12, J.H. Chung13, Y.L. Choi14, M.J. Lee15, M. Ahn16

Author affiliations

  • 1 Medical Oncology, CHA Bundang Medical Center, 120752 - Gyeonggi-do/KR
  • 2 Internal Medicine, Yonsei Severance Hospital Cancer Center, 120752 - Seoul/KR
  • 3 Internal Medicine, Yonsei Severance Hospital Cancer Center, Seoul/KR
  • 4 Medical Oncology, Seoul National University Bundang Hospital, Seongnam-si/KR
  • 5 Medical Oncology, Chungbuk National University Hospital, Cheong-ju/KR
  • 6 Medical Oncology, Kangbuk Samsung Hospital Sungkyunkwan University, Seoul/KR
  • 7 Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR
  • 8 Medical Oncology, Gachon University Gil Hospital, Incheon/KR
  • 9 Medical Oncology, Inje University Haeundae Paik Hospital, Busan/KR
  • 10 Medical Oncology, Veterance Hospital, Seoul, Seoul/KR
  • 11 Medical Oncology, Inje University Busan Paik Hospital, Busan/KR
  • 12 Pathology, Yonsei Cancer Center Yonsei University, Seoul/KR
  • 13 Pathology, Seoul National University Bundang Hospital, Seongnam-si/KR
  • 14 Pathology, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul/KR
  • 15 Medical Oncology, Yonsei Cancer Center, Seoul/KR
  • 16 Medical Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul/KR


Abstract 1911


ROS1 rearrangement is a distinct molecular subset of non-small-cell lung cancer (NSCLC). We investigated the efficacy and safety of ceritinib in patients with ROS1-rearranged NSCLC.


We enrolled 32 patients with advanced NSCLC who tested positive for ROS1 rearrangement by fluorescent in situ hybridization (FISH). ROS1 immunohistochemistry (IHC) and next-generation sequencing (NGS) were performed in available tumor samples. The primary endpoint was objective response rate (ORR) by central independent radiologic review. The secondary endpoints included disease control rate (DCR), duration of response, progression-free survival (PFS), overall survival (OS), toxicity and concordance between FISH, IHC and NGS.


Between June 7, 2013, and February 1, 2016, a total of 404 patients underwent ROS1 prescreening, and 32 ROS1+ (by FISH) patients were enrolled. The median age of all patients was 62 years, and the majority of patients (84%) were never smokers, and all had adenocarcinoma histology. The median number of previous treatments was 3 (range, 2-7) and 17 (53%) patients had received three or more lines of chemotherapy. At the time of the data cut-off (April 18, 2016), the median follow-up was 7.5 months, and 15 (47%) patients had discontinued treatment. The ORR was 63% (95% CI, 45.7-79.3), with 1 complete response and 19 partial responses. The median duration of response was 10.0 months (range, 0.4 + -18.4+). Among 11 tumors that were tested by NGS, we identified 7 ROS1 fusion partners including ROS1-CD74, ROS1-SLC34A2, and ROS1-EZR. The median progression-free survival was 19.3 months (95% CI, 7.2-not reached), and the median overall survival was not reached at the time of the data cut-off. Of 5 patients with retrospectively confirmed brain metastases, intracranial disease control was reported in 4 patients (80%). Gastrointestinal adverse events, mostly grade 1-2, were the most frequent adverse events (80%); these events were manageable.


Ceritinib demonstrated potent clinical activity in patients with advanced, ROS1-rearranged NSCLC, who received at least one prior line of platinum-based chemotherapy. ROS1 rearrangement defines a second molecular subgroup of NSCLC for which ceritinib is highly active.

Clinical trial identification


Legal entity responsible for the study



Novartis Pharmaceutical


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings